Exendin-4 derivatives as dual GLP1/glucagon agonists

US10758592B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Torsten Haack · Frankfurt am Main, DE
• Michael Wagner · Frankfurt am Main, DE
• Bernd Henkel · Frankfurt am Main, DE
• Siegfried Stengelin · Frankfurt am Main, DE
• Andreas Evers · Frankfurt am Main, DE
• Martin Bossart · Frankfurt am Main, DE

Key dates

• Filing date: Dec 11, 2017
• Grant date: Sep 1, 2020
• Expiry date: Dec 11, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.